Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02070575 · ClinicalTrials.gov registry record
Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 200
- Enrollment target
NCT02070575: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02070575 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02070575 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if a new blood test looking at PSA and a group of PSA related proteins in a patient's blood can indicate which men after surgery with a rising PSA could benefit from treatment, and/or indicate which men are at higher risk for recurrence before initial treatment is given.
Interventions
- OTHER blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2014-02-20 |
| Est. Completion | 2023-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02070575
The ClinicalTrials.gov registry entry for NCT02070575 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which blood draw is the first listed.
NCT02070575 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02070575 about?
NCT02070575 is a clinical study titled "Evaluation of Molecular Forms of PSA and Human Kallikrein 2 in a Cohort of Patients With Locally Resected Prostate Cancer But Biochemical Recurrence". The purpose of this study is to investigate if a new blood test looking at PSA and a group of PSA related proteins in a patient's blood can indicate which men after surgery with a rising PSA could benefit from treatment, and/or indicate which men are at higher risk for recurrence before initial trea...
What is the current status of trial NCT02070575?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2014-02-20. Estimated completion is 2023-10-18.
What interventions are being tested in trial NCT02070575?
The interventions under investigation include: blood draw (OTHER).
Who is sponsoring clinical trial NCT02070575?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.